Form 4 Filing for Robinson Chandler

This filing details several transactions made by Robinson Chandler, CEO of Monopar Therapeutics, on September 24, 2026. Chandler acquired 14,056 shares of common stock at $30 per share and an additional 15,000 shares at $14 per share. Concurrently, Chandler disposed of shares in multiple transactions: 10,450 shares at a weighted average of $87.15, 9,638 shares at $87.96, 8,368 shares at $88.97, and 600 shares at $89.79. The filing also notes the exercise of stock options, including 14,056 options with a conversion price of $30 and 15,000 options with a conversion price of $14. A portion of the shares are held indirectly through the Chandler D. Robinson Irrevocable Trust.